Literature DB >> 35412194

Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension.

Karolina Czerwińska1, Małgorzata Poręba2, Adam Prokopowicz3, Lidia Januszewska1, Aleksandra Jaremków1, Iwona Markiewicz-Górka1, Helena Martynowicz4, Grzegorz Mazur4, Rafał Poręba4, Krystyna Pawlas1, Paweł Gać5.   

Abstract

The aim of the study was to determine the relationship between the serum selenium concentration (Se-S) and the blood concentrations of osteoprotegerin (OPG), receptor activator of nuclear factor kappa-Β ligand (RANKL) and the OPG/RANKL ratio in patients with arterial hypertension. The study group comprised 138 patients with arterial hypertension (age: 56.04 ± 11.59 years). Se-S was determined in all the subjects. Based on the Se-S, the following subgroups were distinguished: a subgroup of patients with a lower Se-S ("low-Se", Se-S < median) and a subgroup of patients with a higher Se-S ("high-Se", Se-S ≥ median). Moreover, the blood concentrations of the parameters of bone metabolism and extraskeletal calcification were assessed: OPG and RANKL. The OPG/RANKL ratio was calculated. In the "low-Se" subgroup, the RANKL concentration was statistically significantly lower, and the OPG/RANKL ratio was statistically significantly higher than in the patients in the "high-Se" subgroup. The correlation analysis showed the negative linear relationships between Se-S and OPG (r = - 0.25, p < 0.05) and between Se-S and OPG/RANKL (r = - 0.47, p < 0.05). Moreover, Se-S positively correlated with RANKL (r = 0.33, p < 0.05). In regression analysis, higher body mass index (BMI), smoking and lower Se-S were independently associated with a higher OPG/RANKL ratio, while lower BMI, use of diuretics, β-blockers and ACE inhibitors and lower OPG/RANKL ratio with effective blood pressure control. In summary, in the group of patients with arterial hypertension, lower Se-S is associated with an unfavourable prognostic panel of parameters of bone metabolism and extraskeletal calcification. Lower Se-S is an independent risk factor for a higher OPG/RANKL ratio, which is an independent prediction factor of ineffective blood pressure control in patients with hypertension.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Arterial hypertension; Calcification; Osteoprotegerin; Selenium

Mesh:

Substances:

Year:  2022        PMID: 35412194     DOI: 10.1007/s12012-022-09741-x

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  38 in total

Review 1.  Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.

Authors:  Shreenidhi M Venuraju; Ajay Yerramasu; Roger Corder; Avijit Lahiri
Journal:  J Am Coll Cardiol       Date:  2010-05-11       Impact factor: 24.094

2.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

Review 3.  Selenium in the prevention of atherosclerosis and its underlying mechanisms.

Authors:  Hongmei Liu; Huibi Xu; Kaixun Huang
Journal:  Metallomics       Date:  2017-01-25       Impact factor: 4.526

4.  Relationship of Hypertension to Coronary Atherosclerosis and Cardiac Events in Patients With Coronary Computed Tomographic Angiography.

Authors:  Rine Nakanishi; Lohendran Baskaran; Heidi Gransar; Matthew J Budoff; Stephan Achenbach; Mouaz Al-Mallah; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Kavitha Chinnaiyan; Benjamin J W Chow; Augustin DeLago; Martin Hadamitzky; Joerg Hausleiter; Ricardo Cury; Gudrun Feuchtner; Yong-Jin Kim; Jonathon Leipsic; Philipp A Kaufmann; Erica Maffei; Gilbert Raff; Leslee J Shaw; Todd C Villines; Allison Dunning; Hugo Marques; Gianluca Pontone; Daniele Andreini; Ronen Rubinshtein; Jeroen Bax; Erica Jones; Niree Hindoyan; Millie Gomez; Fay Y Lin; James K Min; Daniel S Berman
Journal:  Hypertension       Date:  2017-06-12       Impact factor: 10.190

Review 5.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

6.  Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants.

Authors:  Lena Tschiderer; Johann Willeit; Georg Schett; Stefan Kiechl; Peter Willeit
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

Review 7.  Biology of RANK, RANKL, and osteoprotegerin.

Authors:  Brendan F Boyce; Lianping Xing
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 8.  Selenium and selenoproteins: it's role in regulation of inflammation.

Authors:  Sneha Hariharan; Selvakumar Dharmaraj
Journal:  Inflammopharmacology       Date:  2020-03-06       Impact factor: 4.473

9.  Osteoprotegerin SNP associations with coronary artery disease and ischemic stroke risk: a meta-analysis.

Authors:  Jine Wu; Xiyang Li; Fan Gao; Shanshan Gao; Jun Lyu; Hua Qiang
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.